Switching from natalizumab to ocrelizumab in patients with multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

Polman

O’Connor

Havrdova

, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Koendgen

Campbell

, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies. Lancet Neurol 2017; 16: 925–933.

Hauser

Bar-Or

Comi

, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376: 221–234.

Genentech. Ocrelizumab & PML, https://www.ocrelizumabinfo.com/content/dam/gene/ocrelizumabinfo/pdfs/progressive-multifocal-leukoencephalopathy.pdf (accessed 1 March 2020).

Alping

Frisell

Novakova

, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 2016; 79: 950–958.